The impact of PRODIGE 7 on the current worldwide practice of CRS-HIPEC for colorectal peritoneal metastases: A web-based survey and 2021 statement by Peritoneal Surface Oncology Group International (PSOGI)

Long‐term survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Waikato, Aotearoa New Zealand: a 12‐year experience

“…The trial has been scrutinized for its small size, short duration of HIPEC (30 min), and resistance to oxaliplatin due to neoadjuvant FOLFOX chemotherapy 18 . Its negative result has driven a shift towards mitomycin‐based HIPEC regimens of longer duration 19 . The role, drug choice, and duration of HIPEC in CRC peritoneal metastasis remain to be clarified by future research.…”

“…18 Its negative result has driven a shift towards mitomycin-based HIPEC regimens of longer duration. 19 The role, drug choice, and duration of HIPEC in CRC peritoneal metastasis remain to be clarified by future research. An in-depth examination of the long-term outcomes of CRC peritoneal metastasis in the Waikato region is warranted as our cohort expands after the current study period.…”

Preface of the Special Issue: “Peritoneal Surface Malignancies (PSM): The SICO (Italian Society of Surgical Oncology) PSM—Oncoteam Experience, Result Analysis, and Studies’ Purpose”

“…The first is the real incidence of the results obtained with perioperative chemotherapy usually combined with surgical cytoreduction. On this subject, contrasting data have been published according to the various primary tumors responsible for peritoneal spread and the ulterior variable, namely, the various drugs used for intraperitoneal therapy make the topic even more complex and still unclear [ 3 ].…”

HIPEC in Complementary Treatment to Cytoreductive Procedures: An Unexplained Issue After the PRODIGE 7 Trial

“…7 Despite 5-year survival rates of 22-43.2% being achieved in patients who underwent macroscopically radical cytoreductive procedures in combination with HIPEC 8 in the last two decades, the results of one randomized trial (PRODIGE-7) 9 negatively influenced the number of cytoreductive procedures with HIPEC performed around the world. 10…”

“…The PRODIGE 7 trial was evaluated in terms of cytostatic agent used (oxaliplatin), duration of intraperitoneal perfusion of the drug (30 min), and systemic chemotherapy based on the FOLFOX treatment administered to the majority of patients (oxaliplatin used in HIPEC). 10,16,17 The group of patients who underwent HIPEC was also heterogeneous in terms of the oxaliplatin dose (460 mg/m 2 in the open method, 360 mg/m 2 in the closed method). In each study group, 44% of patients received oxaliplatinbased chemotherapy before the procedure, of whom 74% in the CRS/HIPEC group received chemotherapy containing oxaliplatin.…”